GSK484

Translational

-

Preclinical

GSK

Asexual blood stages

Product vision	Uncomplicated malaria treatment and resistance management
MOA	Novel and unknown
Key features	Fast killing in vitro and in vivo No resistant mutants identified Low predicted dose (<100 mg) and 200h predicted half-life
Challenges	Human phamacokinetic prediction for low clearance compounds Synthetic route: Palladium used in two chemical steps
Status	Photosafety study completed Pest or pathogen spread modelling
Next milestone	Contract signature First-in-human clinical trial application submission
Previously	Also known as MMV1793192
Project Director	Dr Zaira Rizopoulos